Date: 2015-06-17
Type of information: Licensing agreement
Compound: Duplex vectors
Company: Asklepios BioPharmaceutical (USA - NC) Avexis (USA - IL)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: gene therapy
Disease:
Details: * On June 17, 2015, Asklepios BioPharmaceutical and AveXis have announced entering into a license agreement, which grants AveXis rights to AskBio’s proprietary self-complementary (SC) technology, also known as Duplex vectors. This technology is utilized in AveXis’ Phase I Adeno-Associated Virus (AAV) gene transfer clinical trial in Spinal Muscular Atrophy (SMA1) patients. Under the terms of the agreement, AveXis will maintain non-exclusive access to the use of AskBio’s Duplex vectors to support their SMA-based therapeutic development and commercialization efforts.
Financial terms: While specific financial terms remain undisclosed, generally the agreement involves AskBio receiving an upfront payment, future payments once certain development and commercial milestones are achieved, as well as a potential related product royalty.
Latest news:
